Benzinga | Apr 14, 2021 08:13AM EDT

Cleveland BioLabs Joint Venture Genome Protection Highlights Publication Of TLR5 Agonist, GP532 In Communications Biology

Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication in Communications Biology, a journal of Nature portfolio, describing the creation, properties and preclinical validation of efficacy of a new deimmunized and pharmacologically optimized Toll-like receptor 5 (TLR5) agonist, named GP532.